Protagenic Therapeutics, Inc.
21.3.2024 13:43:15 CET | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing.
On Tuesday, November 21, 2023, the company received a deficiency letter from Nasdaq stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, because it had not maintained a minimum bid price of $1.00 per share for 30 consecutive trading days. The Notification Letter stated that the company had 180 calendar days, or until May 19, 2024, to regain compliance by having a closing bid price of at least $1.00 per share for ten consecutive trading days. On March 19, 2024, the company received a formal notice from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2).
About Protagenic Therapeutics, Inc.:
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit www.protagenic.com.
About PT00114:
PT00114, a 41-amino-acid synthetic peptide, holds promise in treating various neuro-psychiatric conditions, including depression, anxiety, and PTSD. It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels.
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342 Email: alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announces Date and Time for Third Quarter 2026 Earnings and Conference Call7.10.2026 22:05:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / October 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q3 2026 earnings before the market opens on Thursday, November 5, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loa
Surmodics Launches IOL Cartridge Coating Automation Center in Horsham7.10.2026 21:30:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 7, 2026 / Surmodics, a provider of surface technologies and performance coatings for the medical device industry, today announced at the opening of the American Academy of Ophthalmology annual meeting in New Orleans the launch of its IOL Cartridge Coating Automation Center at its Horsham, Pennsylvania site just outside Philadelphia. "The delivery system for an intraocular lens (IOL) combines precision injection-molded parts with a specifically selected lubricious, biofriendly coating," said Chip Hance, CEO of Surmodics. "As IOL manufacturers increasingly seek automated assembly and modern biomaterial formulations, our Automation Center provides automated coating processes designed for efficient production throughout the product lifecycle." The center brings together advanced hydrophilic coating technology, decades of IOL cartridge application expertise, precision coatings processes and automation capabilities in a manufacturing platform developed
Nevada Court Lifts Restriction, Clearing EESystem to Share Recording of November 2024 Meeting7.10.2026 15:00:00 CEST | Press release
LAS VEGAS, NV / ACCESS Newswire / October 7, 2026 / On September 25, 2026, Judge Erika Mendoza of the Eighth Judicial District Court of Nevada, Clark County, entered a written order denying Jason Shurka's motion for a preliminary injunction and granting Michael Bertolacini's motion to dissolve a temporary restraining order that had barred public dissemination of a recording of a November 14, 2024 meeting. The ruling was issued in Case No. A-25-910216-B, Department XXVII, a matter brought by Energy Enhancement System LLC ("EESystem"), Michael Bertolacini and Dr. Sandra Rose Michael against Jason Shurka and other defendants. In its written order, the court stated that its earlier suggestion that Jason Shurka's consent was needed to share the recording was incorrect, and that the restriction was dissolved as of the September 2, 2026 hearing. According to the order, the meeting was recorded on a cellphone by Manny Shurka, Jason Shurka's father, and Jason Shurka produced that recording in t
Steelcase 2025 Impact Report Highlights Progress in Reducing Emissions and Strengthening Communities7.10.2026 15:00:00 CEST | Press release
GRAND RAPIDS, MI / ACCESS Newswire / October 7, 2026 / Steelcase, a global design and thought leader in the world of work, today released its 2025 Impact Report, "Our Work Toward Better Futures." Steelcase recorded reductions in scope 1 and 2 emissions by 33% from its 2019 baseline and activated 324 Better Futures Community partnerships across 38 locations. The report details how Steelcase members, customers and partners are helping communities thrive and moving the organization closer to net zero. "Our commitments to people and the planet help focus the choices we make, the partnerships we build and the value we create," said Megan Blazina, senior vice president, international, digital and strategy at Steelcase, who also leads sustainability and social impact. "The progress in this report reflects how we're turning those commitments into action." As Steelcase looks ahead as a new part of HNI Corporation, the companies' shared focus on the wellbeing of people and the planet provides a
PostSig Expands Enterprise Platform for Financial and Operational Control7.10.2026 15:00:00 CEST | Press release
SAN FRANCISCO, CA / ACCESS Newswire / October 7, 2026 / PostSig today introduced a significant expansion of its enterprise platform, giving Finance, Procurement, Market Data and Operations teams a shared foundation for managing commercial performance. The expansion follows PostSig being named Best Data Governance Solution in WatersTechnology's 2026 Inside Market Data & Inside Reference Data Awards and its first enterprise deployment with data consultancy CJC, which manages market data for a London multi-asset broker. Pricing schedules, service orders, product inventories and entitlements change over time. When teams manage those records separately, they may see individual values but cannot reliably determine which one applies, why it changed, or how the change should affect spend. "Commercial commitments do not stop at the document," said Hendrik Bartel, CEO and Co-Founder of PostSig. "They show up in products, pricing, invoices, entitlements, usage, and accountability. PostSig connect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom